BIENAIME JEAN JACQUES — SEC insider filings
SEC reporting owner CIK 1221590. 86 insider filings on record with FilingPulse; latest filed 2026-09-28.
Transaction summary — filings shown
Covers the 50 most recent of 86 filings on record, filed 2023-02-14 to 2026-09-28. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 24 legs across 17 filings — 56,200 shares, $1,416,338 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 29 legs across 15 filings — 317,500 shares, $28,709,929 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 84.
- Largest priced transaction: sale of 24,439 shares @ $94.55 ($2,310,707) in BIOMARIN PHARMACEUTICAL INC, filed 2023-05-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | Director | 20 | — | 27 legs · 307,000 sh · $28,506,109 | 62 |
| Immunome Inc. (IMNM) | Director | 12 | 11 legs · 46,300 sh · $641,232 | 2 legs · 10,500 sh · $203,820 | 4 |
| Ascendis Pharma A/S (ASND) | Director | 4 | 7 legs · 2,900 sh · $699,336 | — | 2 |
| Keros Therapeutics, Inc. (KROS) | Director | 9 | 6 legs · 7,000 sh · $75,770 | — | 5 |
| INCYTE CORP (INCY) | Director | 5 | — | — | 11 |
Insider filings — BIENAIME JEAN JACQUES
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-28 | 4 | Ascendis Pharma A/S (ASND) | Disposition to issuer (D): 9,160 (derivative) · Grant/award (A): 9,160 (derivative) | EDGAR |
| 2026-08-19 | 4 | Keros Therapeutics, Inc. (KROS) | Purchase (P): 1,000 @ $10.27 | EDGAR |
| 2026-08-18 | 4 | Ascendis Pharma A/S (ASND) | Purchase (P): 1,100 @ $245.85 · Purchase (P): 900 @ $246.91 | EDGAR |
| 2026-07-17 | 4 | Keros Therapeutics, Inc. (KROS) | Purchase (P): 1,000 @ $10.61 | EDGAR |
| 2026-06-17 | 4 | Keros Therapeutics, Inc. (KROS) | Purchase (P): 1,000 @ $10.19 | EDGAR |
| 2026-06-12 | 4 | Immunome Inc. (IMNM) | Grant/award (A): 9,897 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | INCYTE CORP (INCY) | Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Immunome Inc. (IMNM) | Sale (S): 500 @ $19.44 · Sale (S): 10,000 @ $19.41 · Purchase (P): 6,000 @ $19.48 · Purchase (P): 3,500 @ $19.46 · Purchase (P): 1,000 @ $19.27 | EDGAR |
| 2026-06-05 | 4 | Keros Therapeutics, Inc. (KROS) | Grant/award (A): 7,142 @ $0 · Grant/award (A): 7,433 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Ascendis Pharma A/S (ASND) | Purchase (P): 200 @ $223.76 · Purchase (P): 200 @ $222.30 · Purchase (P): 100 @ $223.50 | EDGAR |
| 2026-05-28 | 4 | INCYTE CORP (INCY) | Option exercise (M): 15,000 @ $84.53 · Tax withholding (F): 13,059 @ $97.10 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | Ascendis Pharma A/S (ASND) | Purchase (P): 200 @ $236.24 · Purchase (P): 200 @ $239.37 | EDGAR |
| 2026-05-19 | 4 | Immunome Inc. (IMNM) | Purchase (P): 5,000 @ $20.70 | EDGAR |
| 2026-05-19 | 4 | Keros Therapeutics, Inc. (KROS) | Purchase (P): 1,000 @ $10.58 | EDGAR |
| 2026-04-17 | 4 | Keros Therapeutics, Inc. (KROS) | Purchase (P): 1,000 @ $11.70 | EDGAR |
| 2026-03-12 | 4 | Immunome Inc. (IMNM) | Purchase (P): 1,000 @ $22.12 · Purchase (P): 1,000 @ $21.55 | EDGAR |
| 2026-03-11 | 4 | Keros Therapeutics, Inc. (KROS) | Purchase (P): 2,000 @ $11.21 | EDGAR |
| 2025-06-12 | 4 | Immunome Inc. (IMNM) | Grant/award (A): 18,864 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | INCYTE CORP (INCY) | Grant/award (A): 2,518 @ $0 · Grant/award (A): 9,216 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Keros Therapeutics, Inc. (KROS) | Grant/award (A): 5,250 @ $0 · Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Immunome Inc. (IMNM) | Purchase (P): 5,000 @ $9.38 | EDGAR |
| 2025-03-26 | 4 | Immunome Inc. (IMNM) | Purchase (P): 7,800 @ $7.78 | EDGAR |
| 2025-03-25 | 4 | Immunome Inc. (IMNM) | Purchase (P): 7,000 @ $8.21 | EDGAR |
| 2024-08-19 | 4 | Immunome Inc. (IMNM) | Purchase (P): 7,000 @ $13.94 | EDGAR |
| 2024-06-18 | 4 | Immunome Inc. (IMNM) | Grant/award (A): 11,333 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | INCYTE CORP (INCY) | Grant/award (A): 2,830 @ $0 · Grant/award (A): 12,517 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4 | Keros Therapeutics, Inc. (KROS) | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2024-05-22 | 4 | Immunome Inc. (IMNM) | Purchase (P): 2,000 @ $13.57 | EDGAR |
| 2024-05-21 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Tax withholding (F): 1,202 @ $77.05 | EDGAR |
| 2024-05-13 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Option exercise (M): 20,000 @ $63.10 · Sale (S): 20,000 @ $81.62 · Option exercise (M): 20,000 @ $63.10 · Sale (S): 20,000 @ $81.14 · Option exercise (M): 20,000 (derivative) @ $0 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2024-04-15 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Option exercise (M): 20,000 @ $63.10 · Sale (S): 20,000 @ $90.99 · Option exercise (M): 20,000 @ $63.10 · Sale (S): 20,000 @ $91.26 · Option exercise (M): 20,000 (derivative) @ $0 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Tax withholding (F): 85,209 @ $83.87 | EDGAR |
| 2024-03-07 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Sale (S): 1,000 @ $85.51 · Sale (S): 1,000 @ $86.71 | EDGAR |
| 2024-02-29 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 82,700 @ $0 · Grant/award (A): 35,975 @ $0 · Grant/award (A): 24,926 @ $0 · Sale (S): 1,000 @ $90.35 | EDGAR |
| 2024-02-12 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Code (L): 40 @ $92.60 · Option exercise (M): 15,000 @ $63.10 · Sale (S): 15,000 @ $89.77 · Option exercise (M): 15,000 @ $63.10 · Sale (S): 15,000 @ $88.28 · Option exercise (M): 15,000 (derivative) @ $0 · +1 more | EDGAR |
| 2024-01-11 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Code (L): 50 @ $99.05 · Option exercise (M): 10,000 @ $63.10 · Sale (S): 10,000 @ $98.19 · Option exercise (M): 10,000 @ $63.10 · Sale (S): 10,000 @ $96.38 · Option exercise (M): 10,000 (derivative) @ $0 · +1 more | EDGAR |
| 2023-12-22 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Option exercise (M): 10,000 @ $63.10 · Sale (S): 10,000 @ $93.99 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2023-12-12 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Code (L): 10 @ $85.57 · Grant/award (A): 2,370 @ $0 | EDGAR |
| 2023-11-09 | 4 | Immunome Inc. (IMNM) | Grant/award (A): 40,696 (derivative) @ $0 | EDGAR |
| 2023-08-09 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Sale (S): 4,000 @ $88.10 · Sale (S): 6,000 @ $88.29 | EDGAR |
| 2023-06-16 | 4 | INCYTE CORP (INCY) | Grant/award (A): 2,505 @ $0 · Grant/award (A): 11,294 (derivative) @ $0 | EDGAR |
| 2023-05-16 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Option exercise (M): 39,130 @ $67.81 · Option exercise (M): 7,370 @ $67.81 · Tax withholding (F): 6,337 @ $93.93 · Tax withholding (F): 33,644 @ $93.93 · Option exercise (M): 39,130 (derivative) @ $0 · Option exercise (M): 7,370 (derivative) @ $0 | EDGAR |
| 2023-05-15 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Option exercise (M): 30,000 @ $67.81 · Sale (S): 24,439 @ $94.55 · Sale (S): 5,561 @ $95.22 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2023-05-11 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 317 @ $66.88 · Option exercise (M): 30,000 @ $67.81 · Sale (S): 13,626 @ $94.22 · Sale (S): 14,964 @ $95.49 · Sale (S): 1,410 @ $95.90 · Option exercise (M): 30,000 @ $67.81 · +4 more | EDGAR |
| 2023-04-12 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Option exercise (M): 10,000 @ $67.81 · Sale (S): 10,000 @ $99.56 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2023-04-10 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Option exercise (M): 10,000 @ $67.81 · Sale (S): 10,000 @ $96.13 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2023-03-17 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 36,100 @ $0 · Tax withholding (F): 9,437 @ $87.74 · Tax withholding (F): 88,623 @ $93.41 · Grant/award (A): 49,430 (derivative) @ $0 | EDGAR |
| 2023-03-14 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Option exercise (M): 15,000 @ $67.81 · Sale (S): 15,000 @ $92.28 · Option exercise (M): 8,000 @ $67.81 · Sale (S): 8,000 @ $90.45 · Option exercise (M): 15,000 (derivative) @ $0 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2023-03-02 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 89,700 @ $0 · Grant/award (A): 44,860 @ $0 · Grant/award (A): 32,972 @ $0 | EDGAR |
| 2023-02-14 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Gift (G): 200 @ $0 · Gift (G): 100 @ $0 · Gift (G): 100 @ $0 · Option exercise (M): 15,000 @ $67.81 · Sale (S): 15,000 @ $110.11 · Option exercise (M): 6,000 @ $67.81 · +3 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1221590 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs